These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 36314883)

  • 1. Editorial for "Integrating Postradiotherapy MRI-Detected Lymph Node Necrosis and Pre- and Posttreatment Epstein-Barr Virus-DNA for Risk Stratification in Nasopharyngeal Carcinoma".
    Watanabe H
    J Magn Reson Imaging; 2023 Jul; 58(1):120-121. PubMed ID: 36314883
    [No Abstract]   [Full Text] [Related]  

  • 2. Integrating Postradiotherapy MRI-Detected Lymph Node Necrosis and Pre- and Posttreatment Epstein-Barr Virus-DNA for Risk Stratification in Nasopharyngeal Carcinoma.
    Cao D; Li S; Li H; Liu L; Wang X; Quan T
    J Magn Reson Imaging; 2023 Jul; 58(1):108-119. PubMed ID: 36326089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrating postradiotherapy plasma Epstein-Barr virus DNA and TNM stage for risk stratification of nasopharyngeal carcinoma to adjuvant therapy.
    Hui EP; Li WF; Ma BB; Lam WKJ; Chan KCA; Mo F; Ai QYH; King AD; Wong CH; Guo R; Poon DMC; Tong M; Li L; Lau TKH; Wong KCW; Lam DCM; Lo YMD; Ma J; Chan ATC
    Ann Oncol; 2020 Jun; 31(6):769-779. PubMed ID: 32217076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma.
    Guo R; Tang LL; Mao YP; Du XJ; Chen L; Zhang ZC; Liu LZ; Tian L; Luo XT; Xie YB; Ren J; Sun Y; Ma J
    Cancer; 2019 Jan; 125(1):79-89. PubMed ID: 30351466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic values of the integrated model incorporating the volume of metastatic regional cervical lymph node and pretreatment serum Epstein-Barr virus DNA copy number in predicting distant metastasis in patients with N1 nasopharyngeal carcinoma.
    Yao JJ; Zhou GQ; Wang YQ; Wang SY; Zhang WJ; Jin YN; Zhang F; Li L; Liu LZ; Cheng ZB; Ma J; Qi ZY; Sun Y
    Chin J Cancer; 2017 Dec; 36(1):98. PubMed ID: 29284539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to "Integrating pretreatment MRI-detected nodal features and Epstein-Barr virus DNA to identify optimal candidates for intensity-modulated radiotherapy alone in patients with stage II nasopharyngeal carcinoma".
    Akhtar A; Akhtar R; Nasir BM
    Oral Oncol; 2024 Feb; 149():106674. PubMed ID: 38154446
    [No Abstract]   [Full Text] [Related]  

  • 7. Prognostic value of gross tumor regression and plasma Epstein Barr Virus DNA levels at the end of intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma.
    Liang SB; Zhang N; Chen DM; Yang XL; Chen BH; Zhao H; Lu RL; Chen Y; Fu LW
    Radiother Oncol; 2019 Mar; 132():223-229. PubMed ID: 30366725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epstein-Barr Virus DNA in Nasopharyngeal Carcinoma: A Brief Review.
    Xue F; He X
    Methods Mol Biol; 2020; 2204():99-107. PubMed ID: 32710318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of plasma Epstein-Barr virus DNA level during posttreatment follow-up in the patients with nasopharyngeal carcinoma having undergone intensity-modulated radiotherapy.
    Li WF; Zhang Y; Huang XB; Du XJ; Tang LL; Chen L; Peng H; Guo R; Sun Y; Ma J
    Chin J Cancer; 2017 Nov; 36(1):87. PubMed ID: 29116021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential pitfalls in incorporating plasma Epstein-Barr virus DNA in the management of nasopharyngeal carcinoma.
    Wong ECY; Hung JLC; Ng WT
    Head Neck; 2020 Mar; 42(3):446-455. PubMed ID: 31778007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utilization of the lymph node-to-primary tumor ratio of PET standardized uptake value and circulating Epstein-Barr virus DNA to predict distant metastasis in nasopharyngeal carcinoma.
    Shen EY; Hung TM; Tsan DL; Cheng NM; Kang CJ; Huang SF; Hsu CL; Lin CY; Wang HM; Hsieh JC; Cheng AJ; Fan KH; Chang JT
    Radiother Oncol; 2022 Dec; 177():1-8. PubMed ID: 35568282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Diagnostics of nasopharyngeal carcinoma with Epstein-Barr virus (Herpesviridae, Lymphocryptovirus, HHV-4) serological and molecular markers in cases of undetected primary tumor location.].
    Senyuta NB; Smirnova KV; Kondratova VN; Ignatova AV; Mudunov AM; Dushenkina TE; Liechtenstein AV; Gurtsevich VE
    Vopr Virusol; 2019; 64(5):229-237. PubMed ID: 32167688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor residue in patients with stage II-IVA nasopharyngeal carcinoma who received intensity-modulated radiation therapy: development and validation of a prediction nomogram integrating postradiotherapy plasma Epstein-Barr virus deoxyribonucleic acid, clinical stage, and radiotherapy dose.
    Huang YY; Zhou JY; Zhan ZJ; Ke LR; Xia WX; Cao X; Cai ZC; Deng Y; Chen X; Zhang LL; Huang HY; Guo X; Lv X
    BMC Cancer; 2023 May; 23(1):410. PubMed ID: 37149594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MRI-detected residual retropharyngeal lymph node after intensity-modulated radiotherapy in nasopharyngeal carcinoma: Prognostic value and a nomogram for the pretherapy prediction of it.
    Li WZ; Liu GY; Lin LF; Lv SH; Qiang MY; Lv X; Wu YS; Liang H; Ke LR; Wang DL; Yu YH; Qiu WZ; Liu KY; Guo X; Li JP; Zou YJ; Xiang YQ; Xia WX
    Radiother Oncol; 2020 Apr; 145():101-108. PubMed ID: 31931288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefit of [18F]-FDG PET/CT for treatment-naïve nasopharyngeal carcinoma.
    Yang SS; Wu YS; Chen WC; Zhang J; Xiao SM; Zhang BY; Liu ZQ; Chen EN; Zhang X; OuYang PY; Xie FY
    Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):980-991. PubMed ID: 34468782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymph-node Epstein-Barr virus concentration in diagnosing cervical lymph-node metastasis in nasopharyngeal carcinoma.
    Li H; Huang C; Chen Q; Peng C; Zhang R; Shen J; Chen M; Mai H; Zou R
    Eur Arch Otorhinolaryngol; 2020 Sep; 277(9):2513-2520. PubMed ID: 32240363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amyloid and hyaline globules in undifferentiated nasopharyngeal carcinoma.
    Khan IS; Loh KS; Petersson F
    Ann Diagn Pathol; 2019 Jun; 40():1-6. PubMed ID: 30822626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining plasma Epstein-Barr virus DNA and nodal maximal standard uptake values of 18F-fluoro-2-deoxy-D-glucose positron emission tomography improved prognostic stratification to predict distant metastasis for locoregionally advanced nasopharyngeal carcinoma.
    Chen WH; Tang LQ; Zhang L; Chen QY; Guo SS; Liu LT; Fan W; Zhang X; Guo L; Zhao C; Cao KJ; Qian CN; Guo X; Xie D; Zeng MS; Mai HQ
    Oncotarget; 2015 Nov; 6(35):38296-307. PubMed ID: 26512922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pretreatment Serum Amyloid A and C-reactive Protein Comparing with Epstein-Barr Virus DNA as Prognostic Indicators in Patients with Nasopharyngeal Carcinoma: A Prospective Study.
    Chen QY; Tang QN; Tang LQ; Chen WH; Guo SS; Liu LT; Li CF; Li Y; Liang YJ; Sun XS; Guo L; Mo HY; Sun R; Luo DH; Fan YY; He Y; Chen MY; Cao KJ; Qian CN; Guo X; Mai HQ
    Cancer Res Treat; 2018 Jul; 50(3):701-711. PubMed ID: 28707462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Clinical Value of Plasma Epstein-Barr Virus DNA as a Tumor Marker in Nasopharyngeal Carcinoma: Prognostic? Yes, But How Can We Best Use It?
    Dragovic AF
    Cancer J; 2022 Mar-Apr 01; 28(2):93-95. PubMed ID: 35333491
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.